14 min listen
Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2
Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2
ratings:
Length:
15 minutes
Released:
Sep 5, 2023
Format:
Podcast episode
Description
Please visit answersincme.com/DEV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses TROP2-directed therapies for patients with non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Outline the rationale for incorporating TROP2-directed therapies into the treatment of patients with advanced NSCLC; Explain the latest clinical data supporting the use of emerging TROP2-directed therapies in the treatment of advanced NSCLC; and Identify strategies to maximize the incorporation of TROP2-directed therapies into treatment plans for patients with advanced NSCLC, as they become available.
Released:
Sep 5, 2023
Format:
Podcast episode
Titles in the series (85)
Solange Peters, MD, PhD - Harnessing Frontline Dual Immunotherapy and Chemotherapy Combination Regimens for Advanced NSCLC: Strategies to Enhance Individualized Care: Please visit answersincme.com/BTD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology